NCT07141004View on ClinicalTrials.gov

A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

June 5, 2027

Study Completion Date

September 11, 2027

Conditions
Arthritis, Psoriatic
Interventions
DRUG

Guselkumab

Guselkumab will be administered as subcutaneous injection.

Trial Locations (5)

110060

RECRUITING

Sir Ganga Ram Hospital, New Delhi

380060

RECRUITING

Cims Hospital, Ahmedabad

400016

RECRUITING

P. D. Hinduja National Hospital and Research Center, Mumbai

600004

RECRUITING

Chennai Meenakshi Multispeciality Hospital, Chennai

4110001

RECRUITING

Jehangir Clinical Development Centre, Pune

Sponsors
All Listed Sponsors
lead

Johnson & Johnson Private Limited

INDUSTRY